Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gian-Andrea Thanei

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Therapeutic Innovation & Regulatory Science|April 14, 2025
Futility Interim Analyses - A Plea for SimplicityGian-Andrea Thanei, Gaëlle Klingelschmitt, Claude Berge, et al.
Annals of Clinical and Translational Neurology|March 1, 2022
Development of an age-adjusted model for blood neurofilament light chainChristopher Harp, Gian-Andrea Thanei, Xiaoming Jia, et al.
Ebiomedicine|June 24, 2023
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trialsAmit Bar-Or, Gian-Andrea Thanei, Christopher Harp, et al.
The Lancet. Neurology|January 25, 2025
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAli A Habib, Chongbo Zhao, Inmaculada Aban, et al.
Neurology|January 30, 2025
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label ExtensionJoão J Cerqueira, Achim Berthele, Bruce A C Cree, et al.
Neurology|December 3, 2024
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label TrialHans-Peter Hartung, Ralph H B Benedict, Thomas Berger, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Therapeutic Innovation & Regulatory Science|April 14, 2025
Futility Interim Analyses - A Plea for SimplicityGian-Andrea Thanei, Gaëlle Klingelschmitt, Claude Berge, et al.
Annals of Clinical and Translational Neurology|March 1, 2022
Development of an age-adjusted model for blood neurofilament light chainChristopher Harp, Gian-Andrea Thanei, Xiaoming Jia, et al.
Ebiomedicine|June 24, 2023
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trialsAmit Bar-Or, Gian-Andrea Thanei, Christopher Harp, et al.
The Lancet. Neurology|January 25, 2025
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAli A Habib, Chongbo Zhao, Inmaculada Aban, et al.
Neurology|January 30, 2025
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label ExtensionJoão J Cerqueira, Achim Berthele, Bruce A C Cree, et al.
Neurology|December 3, 2024
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label TrialHans-Peter Hartung, Ralph H B Benedict, Thomas Berger, et al.
Pageof 1